Identification

Name

Famotidine

Accession Number

DB00927

Description

Famotidine is a competitive histamine-2 (H₂) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children.⁸ Compared to other H₂ receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than cimetidine and eight times more potent than ranitidine on a weight basis.² Famotidine is used in various over-the-counter and off-label uses.⁸ While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.⁶

Type

Small Molecule

Groups

Approved

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Famotidine (DB00927)

×

Close

Weight

Average: 337.445
Monoisotopic: 337.044934829

Chemical Formula

C₈H₁₅N₇O₂S₃

Synonyms

• (1-Amino-3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)propylidene)sulfamide
• 3-(((2-((Aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-N-(aminosulfonyl)propanimidamide
• 3-(((2-((Diaminomethylene)amino)-4-thiazolyl)methyl)thio)-N(sup 2)-sulfamoylpropionamidine
• Famotidina
• Famotidine
• Famotidinum
• N-Sulfamoyl-3-((2-guanidinothiazol-4-yl)methylthio)propionamide

External IDs

• L 643341
• MK-208
• YM-11170

Pharmacology

Indication

Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.⁵

It is also indicated in adult patients for the treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine neoplasias) and reduction of the risk of DU recurrence.⁵

The intravenous formulation of famotidine is available for some hospitalized patients with pathological hypersecretory conditions or intractable ulcers or as an alternative to the oral dosage form for short-term use in patients who are unable to take oral medication.⁶

Over-the-counter famotidine is used for the management and prevention of heartburn caused by gastroesophageal reflux in children and adults. Off-label uses of famotidine include the reduction of NSAIDs-associated gastrointestinal effects, treatment of refractory urticarial, prevention of stress ulcer in critically-ill patients, and symptomatic relief of gastritis.^8,9

Associated Conditions

• Bacterial Infection Due to Helicobacter Pylori (H. Pylori)
• Duodenal Ulcer
• Erosive Esophagitis (EE)
• Gastritis
• Heartburn
• Multiple Endocrine Neoplasia
• Stress Ulcers
• Zollinger-Ellison Syndrome
• Active Gastric ulcer
• Acute Duodenal Ulcers
• Gastrointestinal ulceration
• Pathological hypersecretory conditions
• Symptomatic non-erosive gastroesphageal reflux disease

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Famotidine decreases the production of gastric acid, suppresses acid concentration and pepsin content, and decreases the volume of gastric secretion. Famotidine inhibits both basal and nocturnal gastric acid secretion, as well as acid secretion stimulated by food, caffeine, insulin, and pentagastrin.^5,6

Famotidine has a dose-dependent therapeutic action, with the highest dose having the most extended duration of action and the highest inhibitory effect on gastric acid secretion. Following oral administration, the onset of action is within one hour, and the peak effect is reached within 1-3 hours. The duration of effect is about 10-12 hours.¹

Mechanism of action

Histamine acts as a local hormone that stimulates the acid output by parietal cells via a paracrine mechanism. Neuroendocrine cells called enterochromaffin-like (ECL) cells lie close to the parietal cells and regulate the basal secretion of histamine. Histamine release is also promoted from stimulation by acetylcholine and gastrin, a peptide hormone. Gastrin (G) cells release gastrin, which works on CCK₂ receptors on ECL cells. This action promotes the release of histamine from ECL cells. Upon release, histamine acts on H₂ receptors expressed on the basolateral membrane of parietal cells, leading to increased intracellular cAMP levels and activated proton pumps on parietal cells. Proton pump releases more protons into the stomach, thereby increasing the secretion of acid. ⁴ In conditions that are associated with acid hypersecretion such as ulcers, there is a loss of regulation of acid secretion. Famotidine works on H₂ receptors and blocks the actions of histamine.⁸

Target	Actions	Organism
AHistamine H2 receptor	antagonist	Humans

Absorption

Following oral administration, the absorption of famotidine is dose-dependent and incomplete.³ The oral bioavailability ranges from 40-50%, and the Cmax is reached in 1-4 hours post-dosing.^1,3 While the bioavailability can be slightly increased with the intake of food and decreased by antacids, there is no clinical significance.⁵

Volume of distribution

The steady-state volume of distribution ranges from 1.0 to 1.3 L/kg.³ Famotidine is found in breast milk; however, it is found in breast milk at the lowest concentrations compared to other H₂ receptor antagonists.⁸

Protein binding

The protein binding of famotidine is about 15 to 22%.³

Metabolism

Famotidine undergoes minimal first-pass metabolism. About 25-30% of the drug is eliminated through hepatic metabolism. The only metabolite identified in humans is the S-oxide.⁵

Hover over products below to view reaction partners

• Famotidine
  • Famotidine S-oxide

Route of elimination

About 65-70% of the total administered dose of famotidine undergoes renal elimination, and 30-35% of the dose is cleared by metabolism.⁵ Following intravenous administration, about 70% of the drug is eliminated in the urine as an unchanged drug.³

Half-life

The elimination half-life is about 2 to 4 hours.³ The half-life is expected to increase nonlinearly in patients with decreased renal function.¹

Clearance

Renal clearance is 250-450 mL/min, indicating some tubular excretion. Because the renal clearance rate exceeds the glomerular filtration rate, famotidine is thought to be mainly eliminated via both glomerular filtration and renal tubular secretion.³

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

The oral LD₅₀ is 4049 mg/kg in rats and 4686 mg/kg in mice. The subcutaneous LD₅₀ is 800 mg/kg in rats and mice. The lowest published toxic dose (TDLo) in man following oral administration is 4 mg/kg/7D.⁷

Symptoms of overdose resemble the adverse events seen with the use of recommended doses, and they should be responded with supportive and symptomatic treatment. Any unabsorbed drug should be removed from the gastrointestinal tract, and the patient should be monitored accordingly. The use of hemodialysis to eliminate the drug from the systemic circulation is effective, but the experience of using hemodialysis in response to famotidine overdose is limited in clinical settings.⁵

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Famotidine Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Unlock Additional Data
Acebutolol	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acebutolol.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Famotidine.
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Famotidine.
Acetylsalicylic acid	The excretion of Famotidine can be decreased when combined with Acetylsalicylic acid.
Acrivastine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Acrivastine.
Acyclovir	The excretion of Famotidine can be decreased when combined with Acyclovir.
Adenosine	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Adenosine.
Agomelatine	The metabolism of Agomelatine can be decreased when combined with Famotidine.
Ajmaline	The risk or severity of QTc prolongation can be increased when Famotidine is combined with Ajmaline.
Albendazole	The metabolism of Albendazole can be decreased when combined with Famotidine.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

• Avoid excessive or chronic alcohol consumption. Alcohol increases the risk of gastric irritation.
• Limit caffeine intake. Caffeine and other acidic beverages increases the risk of gastric irritation.
• Take with or without food. Food slightly increases bioavailability, but not to a clinically significant extent.

Products

Product Images

PreviousNext

International/Other Brands

Amfamox / Antodine / Confobos / Cronol / Digervin / Dispromil / Duovel / Durater / Famocid / Famosan / Famotep / Famox / Famoxal / Famtac / Famulcer / Fanosin / Gaster / Lecedil / Motiax / Mylanta AR / Notidin / Nulceran / Panalba / Pepcid RPD / Pepcidin / Pepcidine / Pepdine / Pepfamin / Quamatel / Renapepsa / Rubacina / Sedanium-R / Supertidine / Tairal / Tipodex / Ulfagel / Ulfamid / Ulgarine / Vagostal

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Bci Famotidine	Tablet		Oral	Baker Cummins Inc	Not applicable	Not applicable
Bci Famotidine	Tablet		Oral	Baker Cummins Inc	Not applicable	Not applicable
Famotidine	Powder, for suspension	40 mg/5mL	Oral	Paddock Laboratories, Inc.	2010-05-28	2015-04-30
Famotidine	Injection, solution	2 mg/1mL	Intravenous	Cantrell Drug Company	2014-06-11	Not applicable
Famotidine Injection	Solution		Intravenous	Mylan Pharmaceuticals	Not applicable	Not applicable
Famotidine Injection	Solution		Intravenous	Hospira Healthcare Ulc	Not applicable	Not applicable
Famotidine Injection	Solution		Intravenous	Mylan Pharmaceuticals	Not applicable	Not applicable
Famotidine Injection	Solution		Intravenous	Fresenius Kabi	Not applicable	Not applicable
Famotidine IV Injection	Solution		Intravenous	TEVA Canada Limited	Not applicable	Not applicable
Famotidine IV Injection	Solution		Intravenous	TEVA Canada Limited	Not applicable	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Apo-famotidine Injectable	Solution		Intravenous	Apotex Corporation	2003-11-17	2013-08-02
Apo-famotidine Injectable	Solution		Intravenous	Apotex Corporation	2004-05-27	2013-08-02
Apo-famotidine Tab 20mg USP	Tablet		Oral	Apotex Corporation	1993-12-31	Not applicable
Apo-famotidine Tab 40mg USP	Tablet		Oral	Apotex Corporation	1993-12-31	Not applicable
Famotidine	Tablet	20 mg/1	Oral	Proficient Rx LP	2001-04-16	Not applicable
Famotidine	Tablet, coated	20 mg/1	Oral	Teva	2008-04-30	2008-04-30
Famotidine	Tablet	20 mg/1	Oral	Cardinal Health	2001-04-16	Not applicable
Famotidine	Tablet, film coated	20 mg/1	Oral	Wockhardt	2001-04-16	Not applicable
Famotidine	Injection	10 mg/1mL	Intravenous	West-Ward Pharmaceuticals Corp.	2001-04-16	Not applicable
Famotidine	Tablet, film coated	20 mg/1	Oral	A-S Medication Solutions	2001-04-16	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
7 Select Acid Controller	Tablet	20 mg/1	Oral	7-Eleven	2014-08-05	2020-01-31
Acid Control	Tablet		Oral	Vita Health Products Inc	1998-10-27	Not applicable
Acid Control	Tablet		Oral	Apotex Corporation	2000-07-11	Not applicable
Acid Control	Tablet		Oral	TEVA Canada Limited	1997-06-17	2019-07-09
Acid Control	Tablet		Oral	Pendopharm Division Of Pharmascience Inc	1997-09-08	2015-01-19
Acid Control	Tablet		Oral	Apotex Corporation	2014-04-28	Not applicable
Acid Control Original Strength	Tablet	10 mg/1	Oral	Medicine Shoppe International	2009-10-19	2012-04-09
Acid Controller	Tablet, film coated	20 mg/1	Oral	Walgreen Company	2006-09-26	Not applicable
Acid Controller	Tablet, film coated	10 mg/1	Oral	H E B	2015-10-23	Not applicable
Acid Controller	Tablet, film coated	20 mg/1	Oral	H E B	2016-09-14	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Acid Controller Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating	2013-06-05	2017-01-15
Acid Controller Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Safeway	2008-08-06	2017-01-19
Acid Controller Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating	2013-06-05	2016-11-16
Acid Controller Complete dual action	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen	2008-07-30	2017-07-25
Acid Controller Complete dual action	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen Company	2008-07-30	Not applicable
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen Company	2016-01-29	Not applicable
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating Co., LLC	2016-01-12	Not applicable
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Rite Aid	2009-05-15	2017-09-08
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Walgreen Company	2016-01-29	Not applicable
Acid Reducer Complete	Famotidine (10 mg/1) + Calcium carbonate (800 mg/1) + Magnesium hydroxide (165 mg/1)	Tablet, chewable	Oral	Shopko Stores Operating Co., LLC	2016-01-06	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Famotidine	Famotidine (2 mg/1mL)	Injection, solution	Intravenous	Cantrell Drug Company	2014-06-11	Not applicable

Categories

ATC Codes

A02BA03 — Famotidine

• A02BA — H2-receptor antagonists
• A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
• A02 — DRUGS FOR ACID RELATED DISORDERS
• A — ALIMENTARY TRACT AND METABOLISM

A02BA53 — Famotidine, combinations

• A02BA — H2-receptor antagonists
• A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
• A02 — DRUGS FOR ACID RELATED DISORDERS
• A — ALIMENTARY TRACT AND METABOLISM

Drug Categories

• Acid Reducers
• Alimentary Tract and Metabolism
• Anti-Ulcer Agents
• Cytochrome P-450 CYP1A2 Inhibitors
• Cytochrome P-450 CYP1A2 Inhibitors (weak)
• Cytochrome P-450 Enzyme Inhibitors
• Drugs for Acid Related Disorders
• Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
• Gastric Acid Lowering Agents
• Gastrointestinal Agents
• Histamine Agents
• Histamine Antagonists
• Histamine H2 Antagonists
• MATE 1 Inhibitors
• MATE inhibitors
• Neurotransmitter Agents
• OAT3/SLC22A8 Inhibitors
• OAT3/SLC22A8 Substrates
• OCT2 Inhibitors
• Potential QTc-Prolonging Agents
• QTc Prolonging Agents
• Sulfur Compounds
• Thiazoles

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as 2,4-disubstituted thiazoles. These are compounds containing a thiazole ring substituted at the positions 2 and 3.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Azoles

Sub Class

Thiazoles

Direct Parent

2,4-disubstituted thiazoles

Alternative Parents

Organic sulfuric acids and derivatives / Heteroaromatic compounds / Guanidines / Sulfenyl compounds / Propargyl-type 1,3-dipolar organic compounds / Dialkylthioethers / Azacyclic compounds / Amidines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives

show 1 more

Substituents

2,4-disubstituted 1,3-thiazole / Amidine / Aromatic heteromonocyclic compound / Azacycle / Dialkylthioether / Guanidine / Heteroaromatic compound / Hydrocarbon derivative / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfuric acid or derivatives / Organonitrogen compound / Organopnictogen compound / Organosulfur compound / Propargyl-type 1,3-dipolar organic compound / Sulfenyl compound / Thioether

show 9 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

sulfonamide, guanidines, 1,3-thiazole (CHEBI:4975)

Chemical Identifiers

UNII

5QZO15J2Z8

CAS number

76824-35-6

InChI Key

XUFQPHANEAPEMJ-UHFFFAOYSA-N

InChI

InChI=1S/C8H15N7O2S3/c9-6(15-20(12,16)17)1-2-18-3-5-4-19-8(13-5)14-7(10)11/h4H,1-3H2,(H2,9,15)(H2,12,16,17)(H4,10,11,13,14)

IUPAC Name

3-[({2-[(diaminomethylidene)amino]-1,3-thiazol-4-yl}methyl)sulfanyl]-N'-sulfamoylpropanimidamide

SMILES

NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1

References

Synthesis Reference

Montserrat Ballester-Rodes, Francisco E. Palomo-Nicolau, Antonio L. Palomo-Coli, "Famotidine polymorphic forms and their preparation process." U.S. Patent US5021582, issued March, 1987.

US5021582

General References

1. Chremos AN: Clinical pharmacology of famotidine: a summary. J Clin Gastroenterol. 1987;9 Suppl 2:7-12. doi: 10.1097/00004836-198707002-00003. [PubMed:2887616]
2. Langtry HD, Grant SM, Goa KL: Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases. Drugs. 1989 Oct;38(4):551-90. doi: 10.2165/00003495-198938040-00005. [PubMed:2573505]
3. Echizen H, Ishizaki T: Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991 Sep;21(3):178-94. doi: 10.2165/00003088-199121030-00003. [PubMed:1764869]
4. 29. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 360-363). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
5. FDA Approved Drug Products: PEPCID (famotidine) tablets, for oral use [Link]
6. Mylan Pharmaceuticals Product Monograph: Famotidine, for intravenous injection [Link]
7. Cayman Chemical: Famotidine MSDS [Link]
8. Famotidine - StatPearls - NCBI Bookshelf [Link]
9. Prophylaxis and management of stress ulceration - NCBI [Link]

External Links

Human Metabolome Database

HMDB0001919

KEGG Drug

D00318

PubChem Compound

3325

PubChem Substance

46507397

ChemSpider

3208

BindingDB

50036754

RxNav

4278

ChEBI

4975

ChEMBL

CHEMBL902

ZINC

ZINC000001530636

Therapeutic Targets Database

DAP000341

PharmGKB

PA449586

RxList

RxList Drug Page

Drugs.com

Drugs.com Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Famotidine

AHFS Codes

• 56:28.12 — Histamine H2-antagonists

FDA label

Download (1.05 MB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Not Available	Human Immunodeficiency Virus (HIV) Infections	2
4	Completed	Diagnostic	Acute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI)	1
4	Completed	Prevention	Acute Coronary Syndromes (ACS) / Acute Myocardial Infarction (AMI)	1
4	Completed	Prevention	Marginal Ulcers	1
4	Completed	Prevention	Peptic Ulcer	1
4	Completed	Prevention	Peptic Ulcer/Erosions	1
4	Completed	Prevention	Pulmonary Aspiration of Gastric Contents	1
4	Completed	Prevention	Ulcers	1
4	Completed	Treatment	Coronary Heart Disease (CHD) / Gastrointestinal Bleeding	1
4	Completed	Treatment	Heartburn	1

Pharmacoeconomics

Manufacturers

• Lupin ltd
• Navinta llc
• Salix pharmaceuticals inc
• Akorn strides llc
• Apotex inc richmond hill
• Apothecon inc div bristol myers squibb
• App pharmaceuticals llc
• Baxter healthcare corp anesthesia and critical care
• Baxter healthcare corp
• Bedford laboratories div ben venue laboratories inc
• Hospira inc
• Ben venue laboratories inc
• Claris lifesciences ltd
• Abbott laboratories
• Baxter healthcare internati0nal specialty therapies div
• Merck research laboratories div merck co inc
• L perrigo co
• Schwarz pharma inc
• Actavis elizabeth llc
• Alembic ltd
• Apotex inc
• Carlsbad technology inc
• Dr reddys laboratories ltd
• Genpharm inc
• Ivax pharmaceuticals inc sub teva pharmaceuticals usa
• Mutual pharmaceutical co inc
• Mylan pharmaceuticals inc
• Perrigo co
• Ranbaxy laboratories inc
• Sandoz inc
• Teva pharmaceuticals usa inc
• Watson laboratories inc
• Wockhardt ltd
• Wockhardt americas inc

Packagers

• Advanced Pharmaceutical Services Inc.
• Akorn Inc.
• Amerisource Health Services Corp.
• APP Pharmaceuticals
• A-S Medication Solutions LLC
• Atlantic Biologicals Corporation
• Baxter International Inc.
• Bedford Labs
• Ben Venue Laboratories Inc.
• Bryant Ranch Prepack
• Cardinal Health
• Carlsbad Technology Inc.
• Chain Drug
• Corepharma LLC
• CVS Pharmacy
• Dispensing Solutions
• Diversified Healthcare Services Inc.
• Doctor Reddys Laboratories Ltd.
• H.J. Harkins Co. Inc.
• Heartland Repack Services LLC
• Hospira Inc.
• Ivax Pharmaceuticals
• Johnson & Johnson Healthcare
• Kaiser Foundation Hospital
• Lake Erie Medical and Surgical Supply
• Legacy Pharmaceuticals Packaging LLC
• Lupin Pharmaceuticals Inc.
• Major Pharmaceuticals
• Mckesson Corp.
• Medisca Inc.
• Merck & Co.
• Murfreesboro Pharmaceutical Nursing Supply
• Mylan
• Northstar Rx LLC
• Nucare Pharmaceuticals Inc.
• PCA LLC
• PD-Rx Pharmaceuticals Inc.
• Perrigo Co.
• Pharmaceutical Utilization Management Program VA Inc.
• Pharmedium
• Physicians Total Care Inc.
• Preferred Pharmaceuticals Inc.
• Prepackage Specialists
• Prepak Systems Inc.
• Rebel Distributors Corp.
• Redpharm Drug
• Remedy Repack
• Salix Pharmaceuticals
• Sandhills Packaging Inc.
• Southwood Pharmaceuticals
• Strides Arcolab Limited
• Teva Pharmaceutical Industries Ltd.
• UDL Laboratories
• Vangard Labs Inc.
• Walgreen Co.
• Watson Pharmaceuticals
• Wockhardt Ltd.
• Yung Shin Pharmaceutical Industry Ltd.
• Zydus Pharmaceuticals

Dosage Forms

Form	Route	Strength
Tablet, film coated	Oral	20 mg/1
Tablet, coated	Oral
Tablet, film coated	Oral	20 MG
Tablet, film coated	Oral	40 MG
For suspension	Oral	40 mg/5mL
Injection	Intravenous	10 mg/1mL
Injection, solution	Intravenous	10 mg/1mL
Injection, solution	Intravenous	2 mg/1mL
Powder, for solution	Oral	40 mg/5mL
Powder, for suspension	Oral	40 mg/5mL
Tablet	Oral	10 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	40 mg/1
Tablet, coated	Oral	20 mg/1
Tablet, coated	Oral	40 mg/1
Tablet, film coated	Oral	10 mg/1
Tablet, film coated	Oral	40 mg/1
Tablet, film coated, extended release	Oral	10 mg/1
Solution	Intravenous
Tablet, orally disintegrating	Oral	20 mg/1
Tablet, orally disintegrating	Oral	40 mg/1
Tablet, chewable	Oral
Injection, solution	Intravenous	20 mg/50mL
Injection, solution, concentrate	Intravenous	10 mg/1mL
Tablet	Oral	10 mg
Tablet, chewable	Oral	20 mg/1
Tablet	Oral
Tablet, coated	Oral	10 mg/1

Prices

Unit description	Cost	Unit
Pepcid 30 40 mg tablet Bottle	125.5USD	bottle
Pepcid 40 mg/5ml Suspension 50ml Bottle	123.88USD	bottle
Pepcid 30 20 mg tablet Bottle	64.13USD	bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 710ml Bottle	10.15USD	bottle
Mylanta 200-200-20 mg/5ml Suspension 710ml Bottle	9.23USD	bottle
Mylanta 200-200-20 mg/5ml Suspension 355ml Bottle	7.99USD	bottle
Mylanta Double-Strength 400-400-40 mg/5ml Suspension 355ml Bottle	7.99USD	bottle
Famotidine 40 mg tablet	3.43USD	tablet
Pepcid 40 mg tablet	3.02USD	tablet
Famotidine powder	2.74USD	g
Famotidine 20 mg tablet	1.76USD	tablet
Pepcid 20 mg tablet	1.6USD	tablet
Apo-Famotidine 40 mg Tablet	1.11USD	tablet
Mylan-Famotidine 40 mg Tablet	1.11USD	tablet
Novo-Famotidine 40 mg Tablet	1.11USD	tablet
Nu-Famotidine 40 mg Tablet	1.11USD	tablet
Pepcid ac 10 mg tablet	0.72USD	tablet
Famotidine 40 mg/4 ml vial	0.71USD	ml
Famotidine 500 mg/50 ml vial	0.71USD	ml
Apo-Famotidine 20 mg Tablet	0.62USD	tablet
Mylan-Famotidine 20 mg Tablet	0.62USD	tablet
Novo-Famotidine 20 mg Tablet	0.62USD	tablet
Nu-Famotidine 20 mg Tablet	0.62USD	tablet
Pepcid ac 20 mg tablet	0.58USD	tablet
Famotidine-ns 20 mg/10 ml syrg	0.54USD	ml
Pepcid ac 10 mg gelcap	0.48USD	capsule
Pepcid complete tablet chew	0.4USD	tablet
Famotidine 20 mg/2 ml vial	0.36USD	ml
Famotidine 10 mg/ml vial	0.28USD	ml
CVS Pharmacy acid controller 20 mg tablet	0.24USD	tablet
CVS Pharmacy acid controller tablet	0.24USD	tablet
Acid reducer 20 mg tablet	0.22USD	tablet
Acid controller 10 mg tablet	0.21USD	tablet
Mylanta gas 125 mg tablet chew	0.16USD	tablet
Acid reducer 10 mg tablet	0.15USD	tablet
Famotidine 10 mg tablet	0.15USD	tablet
Famotidine 20 mg piggyback	0.13USD	ml
Mylanta gelcap	0.12USD	capsule
Mylanta ultimate-strength tablet	0.07USD	tablet
Mylanta ultra chew tablet	0.06USD	tablet
Pv acid reducer 10 mg tablet	0.05USD	tablet
Mylanta liq	0.02USD	ml
Mylanta supreme antacid liq	0.02USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
Unlock Additional Data
US5075114	No	1991-12-24	2010-05-23
CA2178277	No	2000-11-14	2016-06-05
CA2052679	No	1997-12-02	2011-08-21
US6221392	No	2001-04-24	2018-04-09
US6024981	No	2000-02-15	2018-04-09
US5854267	Yes	1998-12-29	2016-06-29
US6814978	Yes	2004-11-09	2022-02-26
US5989588	Yes	1999-11-23	2018-03-30
US8067451	No	2011-11-29	2026-07-18
US8501228	No	2013-08-06	2026-07-18
US8318202	No	2012-11-27	2026-07-18
US8449910	No	2013-05-28	2026-07-18
US8309127	No	2012-11-13	2026-07-18
US8067033	No	2011-11-29	2026-07-18
US5667794	Yes	1997-09-16	2015-11-02

Additional Data Available

Filed On
Filed On
The date on which a patent was filed with the relevant government.
Learn more

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	163.5 °C	PhysProp
water solubility	1000 mg/L (at 20 °C)	MERCK INDEX (1996)
logP	-0.64	ISLAM,MS & NARURKAR,MM (1993)

Predicted Properties

Property	Value	Source
Water Solubility	0.271 mg/mL	ALOGPS
logP	-0.2	ALOGPS
logP	-2	ChemAxon
logS	-3.1	ALOGPS
pKa (Strongest Acidic)	9.29	ChemAxon
pKa (Strongest Basic)	8.38	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	175.83 Å2	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	80.46 m3·mol-1	ChemAxon
Polarizability	31.66 Å3	ChemAxon
Number of Rings	1	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9156
Blood Brain Barrier	+	0.9382
Caco-2 permeable	-	0.8957
P-glycoprotein substrate	Non-substrate	0.5839
P-glycoprotein inhibitor I	Non-inhibitor	0.9044
P-glycoprotein inhibitor II	Non-inhibitor	0.8701
Renal organic cation transporter	Non-inhibitor	0.6802
CYP450 2C9 substrate	Non-substrate	0.7898
CYP450 2D6 substrate	Non-substrate	0.9115
CYP450 3A4 substrate	Non-substrate	0.7558
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Non-inhibitor	0.9231
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Non-inhibitor	0.8309
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9297
Ames test	Non AMES toxic	0.5827
Carcinogenicity	Non-carcinogens	0.9182
Biodegradation	Not ready biodegradable	0.9324
Rat acute toxicity	1.9523 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8366
hERG inhibition (predictor II)	Inhibitor	0.6481

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
MS/MS Spectrum - Quattro_QQQ 10V, N/A	LC-MS/MS	splash10-000i-0029000000-087ab7a1109f0568738d
MS/MS Spectrum - Quattro_QQQ 25V, N/A	LC-MS/MS	splash10-0udi-0900000000-d8a9ef8fc58c0c705232
MS/MS Spectrum - Quattro_QQQ 40V, N/A	LC-MS/MS	splash10-000i-0900000000-e245f325e8c6f31a5fd0
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
MS/MS Spectrum - Linear Ion Trap , negative	LC-MS/MS	splash10-0005-0940000000-a2bd7381011d29592cea
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-0a4i-0090000000-10306158f008021f19a5
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-014i-0090000000-90a70a7303c968311864
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-001i-0090000000-ac0250ad61059e58f431
MS/MS Spectrum - Linear Ion Trap , positive	LC-MS/MS	splash10-0002-0090000000-235724a37e50732fdf94
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4r-0950000000-0c16a77af1ba782fa15a
MS/MS Spectrum - , positive	LC-MS/MS	splash10-0a4r-0950000000-02af106b93d1423b1342
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on June 13, 2005 07:24 / Updated on August 02, 2020 22:18